Highlights

• Integral Diagnostics gained 0.66% to $2.295 on 4 September 2026

• FY26 Revenue and other income reached A$788.7 million, up 25.6%

• Operating EBITDA improved to A$164.8 million with a 20.9% Margin in FY26

• Operating NPAT surged 50.1% to A$47.4 million in FY26

Integral Diagnostics Ltd (ASX:IDX) ticked higher by 0.66% to $2.295 on 4 September 2026. The radiology and diagnostic imaging group has delivered a strong FY26 result, with revenue growth of over 25% and a 50% jump in operating net profit — numbers that are keeping the stock in positive territory.

About the Company

Integral Diagnostics is an Australian radiology and diagnostic imaging company with operations in Victoria, Queensland, Western Australia, South Australia and New Zealand. The company provides a broad range of imaging services including MRI, CT, X-ray, ultrasound and nuclear medicine. IDX has grown through both organic expansion and strategic acquisitions, and has developed a digital-first model to improve workflow efficiency and imaging access for patients and referrers.

Key Developments

For FY26, Integral Diagnostics reported revenue and other income of A$788.7 million, up 25.6%, while operating EBITDA increased to A$164.8 million, with the margin reaching 20.9%. Operating NPAT rose 50.1% to A$47.4 million, and operating free Cash Flow increased 30.7% to A$106.4 million.

Key Catalysts to Watch

• FY2027 guidance and revenue trajectory after a strong FY26 result

• Continued expansion of imaging clinic network through organic growth and acquisitions

• Medicare bulk-billing policy settings supporting diagnostic imaging volumes

• Digital workflow improvements driving efficiency and margin gains

Risks

• Radiologist shortage risk impacting capacity and service delivery

• Government changes to Medicare rebates for diagnostic imaging

• Integration risk from acquisition-led growth strategy

• Competition from other radiology chains including Healius and Capitol Health

Conclusion

Integral Diagnostics has delivered an impressive set of FY26 numbers, with revenue, margins and profit all moving in the right direction. The 50% jump in operating NPAT is particularly striking and reflects both top-line growth and improving operational leverage. The 0.66% gain on 4 September is modest relative to the result's quality, suggesting the market may already have priced in much of the good news. Investors will be watching FY2027 guidance and the sustainability of margin gains closely.